We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
Editorial

Analytical considerations to support expeditious formulation development of vaccines

    Prashant Kumar

    *Author for correspondence:

    E-mail Address: prashant.kumar@ku.edu

    Department of Pharmaceutical Chemistry, Vaccine Analytics & Formulation Center, University of Kansas, Lawrence, KS 66047, USA

    Search for more papers by this author

    &
    Vibhuti Agrahari

    **Author for correspondence:

    E-mail Address: vibhuti-agrahari@ouhsc.edu

    Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, 1110 N. Stonewall Avenue, Oklahoma City, OK 73117, USA

    Search for more papers by this author

    Published Online:11 Jul 2023https://doi.org/10.4155/bio-2023-0090
    Free first page

    References

    • 1. Verch T, Trausch JJ, Shank-Retzlaff M. Principles of vaccine potency assays. Bioanalysis 10(3), 163–180 (2018).
      CASGoogle Scholar
    • 2. Sanyal G. Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. NPJ Vaccines 7(1), 1–10 (2022).
      MedlineGoogle Scholar
    • 3. Schofield TL. Vaccine stability study design and analysis to support product licensure. Biologicals 37(6), 387–396 (2009).
      Medline CASGoogle Scholar
    • 4. Kumar P, Shukla RS, Patel A et al. Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries. Hum. Vaccin. Immunother. 17(7), 2298–2310 (2021).
      Medline CASGoogle Scholar
    • 5. Kumar P, Pullagurla SR, Patel A et al. Effect of formulation variables on the stability of a live, rotavirus (RV3-BB) vaccine candidate using in vitro gastric digestion models to mimic oral delivery. J. Pharm. Sci. 110(2), 760–770 (2021).
      Medline CASGoogle Scholar
    • 6. Wan Y, Gupta V, Bird C et al. Formulation development and improved stability of a combination measles and Rubella live-viral vaccine dried for use in the Nanopatch™ microneedle delivery system. Hum. Vaccin. Immunother. 17(8), 2501–2516 (2021).
      Medline CASGoogle Scholar
    • 7. Kumar P, Wang M, Kumru OS et al. Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate. Mol. Ther. - Methods Clin. Dev. 30, 103–121 (2023).
      CASGoogle Scholar
    • 8. InDevR. VaxArray®platform. www.indevr.com/products/vaxarray/
      Google Scholar
    • 9. LumaCyte. Vaccines & viral infectivity. www.lumacyte.com/application/vaccines-viral-infectivity
      Google Scholar
    • 10. Bio-Rad. qPCR assay design and optimization. www.bio-rad.com/en-us/applications-technologies/qpcr-assay-design-optimization?ID=LUSO7RIVK
      Google Scholar
    • 11. Cumming GF, Fidler F, Vaux DL. Error bars in experimental biology. J. Cell Biol. 177(1), 7–11 (2007).
      Medline CASGoogle Scholar
    • 12. Pullagurla SR, Kumar P, Ogun O et al. Modeling the long-term 2–8 degrees C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated stability data. Biologicals 75, 21–28 (2022).
      Medline CASGoogle Scholar